Persistent Hepatitis A infection: case report by Ngunga, M & Shah, MV
174 EAST AFRICAN MEDICAL JOURNAL April 2010 
East African Medical Journal Vol. 87 No. 4 April 2010
PERSISTENT HEPATITIS A INFECTION: CASE REPORT 
M. Ngunga, MBChB, MMed and M.V. Shah, MBChB, MMed, Consultant Physician and Gastroenterologist, The Aga 
Khan University Hospital Nairobi, P.O. Box 30270-00100, Nairobi, Kenya 
Request for reprints to:  Dr. M. Ngunga, Aga Khan University Hospital Nairobi, P.O. Box 30270-00100, Nairobi, Kenya 
PERSISTENT HEPATITIS A INFECTION: CASE REPORT
 
M. NGUNGA and M.V. SHAH
SUMMARY
Hepatitis A viral infection resolves completely within six months in all patients 
infected. The case presented is a rare one that took fifteen months to resolve from 
hepatitis A viral infection.
INTRODUCTION
Hepatitis A has plagued human kind for centuries 
by causing acute hepatitis associated with significant 
morbidity and occasional mortality. The hepatitis A 
virus (HAV) was identified in 1973 and since then 
extensive research has led to the development of 
vaccines; reducing the mortality and the morbidity of 
the disease. Normally HAV infection is an acute illness 
that resolves in days to weeks except for few cases that 
may progress to fulminant hepatitis sometimes with 
fatal outcome (1). We present a rare case of persistent 
HAV infection that may shed some light into unknown 
virology of the hitherto benign virus. 
CASE REPORT
A 28 year old man was presented to this hospital in 
March 2007 with three months history of jaundice 
and pruritus. Symptoms started with a febrile illness, 
anorexia and he noticed darkening of the urine. There 
was no vomiting and he did not report any change 
in the stool colour. He reported good health prior 
to this and has not been on any medication neither 
has he required hospitalisation or blood transfusion. 
He works in a cement factory where he deals with 
machine maintenance using lubrication oil. He is 
married with one child and does not report anyone at 
his home or work place with icteral or febrile illness. 
He does not use any drugs of abuse and does not 
consume alcohol. He had not travelled anywhere 
outside the country or interacted with world animals. 
There was no family history of any chronic illness. 
 On examination he was awake and alert without 
any features of encephalopathy and his oxygen 
saturation was 98% while breathing ambient air 
with a respiratory rate of 20 breaths per minute. He 
did not have any visible drug injection sites. He had 
scleral and palmer jaundice. He was not pale, did not 
have any palpable nodes and did not have features 
of chronic liver disease. The pulse was regular at 70 
bpm and blood pressure was 112/60mmHg. The 
temperature was 36.3°C. Abdominal examination 
revealed excoriation marks in the anterior abdominal 
wall. The abdomen was soft to palpation with some 
tenderness over the right hypochondrium. The liver 
was palpable 2cm below the right costal margin with 
a smooth tender edge and a span of 12cm. The spleen 
was not palpable and there were no other palpable 
masses. There was no ascitis. Bowel sounds were 
normal and hernial orifices were intact. Neurological, 
respiratory and cardiovascular examinations were 
normal. A diagnosis of acute hepatitis was made 
probably of infectious aetiology. An obstructive cause 
could not be ruled out. 
 The patient was admitted for evaluation. He was 
investigated and discharged on the third hospital day 
on cholestyramine 4g three times a day, B1/B6/B12 
multivitamin complex and advised to rest at home. 
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The creatinine was 48mmol/L, BUN 1.8mmol/L, 
Na 139mmol/L and hypokalemia of 2.9mmol/L 
that was replaced with KCI infusion over the next 
24 hours and normalised. The haemoglobin was 
14.8g/dL, white cell count of 5.3x109 with normal 
distribution and platelets of 327x109. The blood 
glucose was 4.5mmol/L at admission and remained 
normal during the course of follow up. Elisa screen 
for HBsAg and HCV antibody were negative, so 
was HIV I and II serology. A liver ultrasound done 
showed homogenous echogenicity of the liver with 
no dilated ducts. The gall bladder was collapsed 
and the common bile duct was normal. Urinalysis 
done at the time of admission showed bilirubin +++ 
and trace albumin with rest of the parameters being 
normal. Hepatitis A Ig G and Ig M antibodies were 
positive and titres at admission and during follow 
up are as shown below: - 
Date  IgM  IgG 
24/03/2007  4.36  0.093
 (Reactive)  (Reactive) 
21/09/2007  1.76 
 (Reactive)  
15/06/2009  0.69  0.091 
 (Non-reactive)  (Reactive) 
Other causes of hepatitis had to be ruled out after the 
patients liver function tests failed to improve after 
three months. Autoimmune screen was done that 
was negative for anti-nuclear antibodies (ANA), anti-
mitochondrial antibodies (AMA) and anti-smooth 
muscle antibodies (ASMA). Serum ferration was 
normal at 125.3ng/ml (16-323). Alpha-lantitrypsin 
was normal at 197mg/dL (90-200) with EBV IgM 
antibodies being negative. The IgG was reactive. 
Serum ceruloplasmin level was marginally elevated 
at 58.9mg/dL (20-60) that can be expected following 
acute hepatitis. Haemoglobin electrophoresis showed 
Hb AA. 
 The patient declined a liver biopsy. He was lost to 
follow up and was called up to review his progress. As 
can be noted in the table above the liver function test 
normalised two years later with normal bilirubin and 
transaminase levels. The INR was 1.1. The hepatitis 
A Ig G antibody remained positive while the Ig M 
was now negative. 
DISCUSSION
Acute hepatitis A virus (HAV) infection is usually 
a self-limited disease conferring lifelong immunity. 
The disease affects the entire human race with higher 
prevalence in the developing world compared to the 
developed world. The incidence rates are 5.9 per 
100,000 and 1.2 per 100,000 respectively (2,3). The 
above surveillance reports also confirm more than 
90% reduction in the incidence of HAV infection in 
the 1990s after the introduction of the vaccine and 
improved living conditions. 
 HAV is spread via the foecal-oral route, and 
is more prevalent in low socioeconomic areas in 
which lack of adequate sanitation and poor hygienic 
Table 1
The liver function tests before admission, at admission and during follow up  
Date  Total  Direct  ALP  GGT  SGO  SGPT  T. protein  Albumin  INR 
 bilirubin  (mmol/L)  (u/L)  (u/L)  T  (u/L)    (g/L)  
 (mmol/L)     (u/L)   (g/L)   
Normal  1-17  <4  60-120 <50  <37  <40  60-80  32-52  
13/04/2007  391  223  236  64  103  194    
21/03/2007  547  268  412  17  163  172    
24/03/2007        66  33  1.36 
27/0312007          1.25 
20/04/2007  444  180  387  20  208  229    1.43 
18/05/2007  436  196  335  22  137  142  62  34  1.8 
29/06/2007  480  216  391  24  210  170  70  33  
27/07/2007  424  201  449  29  185  135  68  32  2.4 
24/08/2007  429  216  402  21  227  192  72  35  2.65 
21/09/2007  408  208  428  24  255  237    
02/11/2007  385  196  391  26  248  212  67  35  2.47 
30/11/2007  401  196  437  28  290  240  73  34  3 
11/01/2008  382  179  437  32  290  206  64  32  3.3 
13/03/2008  332  175  517  34  182  140  66  31  2.7 
15/06/2009  5  1  118  52  27  34  77  41  1.1 
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practices facilitate spread of the infection. Other 
risk factors include sexual and household contact 
with another person with hepatitis A, homosexual 
activity in men, food or waterborne outbreaks, child 
or employee in a daycare center and injection drug 
use (4). Maternal-foetal transmission has not been 
reported. 
 Injury to the liver is secondary to the host’s 
immune response. Replication of HAV occurs 
exclusively within the cytoplasm of the hepatocyte, 
where the virus causes a non cytopathic infection. 
Hepatocellular damage and destruction of infected 
hepatocytes is mediated by HLA-restricted, HAV-
specific CD8+ T lymphocytes and natural killer cells. 
Interferon gamma promotes the clearance of infected 
hepatocytes. An excessive host response (observable 
clinically by a marked degree of reduction of HAV 
RNA during acute infection) is associated with severe 
hepatitis. 
 Fulminant hepatitis is uncommon but has been 
described in some settings such as in patients with 
preexisting chronic hepatitis C (5). Chronic liver 
disease does not occur except in rare individuals in 
whom hepatitis A virus infection serves as a trigger for 
the development of autoimmune hepatitis. Infection 
also tends to be more severe in adults compared 
to children but neither concomitant hepatitis B or 
C infection or older age are known risk factors for 
persistent infection. 
 One of the atypical presentations of HAV 
infection is cholestatic hepatitis. The clinical course 
in this setting is characterised by marked jaundice, 
pruritus, fever, weight loss, diarrhoea, and malaise. 
Biochemical and serologic abnormalities typically 
show marked elevation of the serum bilirubin 
(often >170mmol/L) and alkaline phosphatase, an 
elevated serum cholesterol, minimal elevation of 
serum aminotransferases, and often IgM anti-HAY 
antibodies. Peak bilirubin levels may be reached in 
the eighth week or later. The jaundice and pruritus 
may last for 12 weeks or more, but are followed by 
complete recovery (6). In the case series quoted above 
involving six patients cholestasis persisted for 12 
weeks with complete recovery but our patient had 
bilirubin levels more than 20 times of the normal 
and elevation of transaminases more than five times 
normal for at least  year.  
 The other atypical form is a relapsing form of 
hepatitis seen in 3-20% of patients with acute hepatitis 
A (7-9). Bilirubin and transaminase levels remain 
elevated for 3-5 weeks then normalise for a similar 
duration of time. A relapse occurs in approximately 
3 weeks mimicking the initial episode but usually 
milder. The entire illness lasts approximately 40 weeks 
and HA V Ig M may remain positive. Our patient did 
not show any signs of relapse but a persistent illness 
with elevated bilirubin, alkaline phosphatase and 
transaminases. 
 The patient did not exhibit any extra-hepatic 
disease. During the course of his disease there were 
no skin lesions and he did not have arthritis. The 
autoimmune markers were negative so autoimmune 
hepatitis was unlikely. 
 The patient declined a liver biopsy that would 
probably have shed some light as to the histological 
findings contributing to his illness. However, we have 
no doubt that hepatitis A was responsible for the 
pathology. This is the first case to confirm persistent 
HAV infection for more than a year. The patient did 
not exhibit any risk factors for persistent disease; 
therefore viral factors may be responsible for his 
protracted illness. 
Disclosures: There are no disclosures relating to this 
article. 
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